ATE369435T1 - Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen - Google Patents

Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen

Info

Publication number
ATE369435T1
ATE369435T1 AT00956962T AT00956962T ATE369435T1 AT E369435 T1 ATE369435 T1 AT E369435T1 AT 00956962 T AT00956962 T AT 00956962T AT 00956962 T AT00956962 T AT 00956962T AT E369435 T1 ATE369435 T1 AT E369435T1
Authority
AT
Austria
Prior art keywords
sequence
gene
vectors
expression
transcription
Prior art date
Application number
AT00956962T
Other languages
English (en)
Inventor
Yoshiyuki Nagai
Atsushi Kato
Mamoru Hasegawa
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Application granted granted Critical
Publication of ATE369435T1 publication Critical patent/ATE369435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
AT00956962T 1999-09-06 2000-09-06 Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen ATE369435T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25223199 1999-09-06

Publications (1)

Publication Number Publication Date
ATE369435T1 true ATE369435T1 (de) 2007-08-15

Family

ID=17234351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00956962T ATE369435T1 (de) 1999-09-06 2000-09-06 Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen

Country Status (13)

Country Link
US (1) US7144579B2 (de)
EP (1) EP1211318B1 (de)
JP (1) JP3748535B2 (de)
KR (1) KR100776086B1 (de)
CN (1) CN1367839A (de)
AT (1) ATE369435T1 (de)
AU (1) AU6872000A (de)
CA (1) CA2376106A1 (de)
DE (1) DE60035885T2 (de)
DK (1) DK1211318T3 (de)
ES (1) ES2288866T3 (de)
HK (1) HK1047450A1 (de)
WO (1) WO2001018223A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
HK1047959A1 (en) * 2000-01-19 2003-03-14 Dnavec Research Inc. Use of paramyxovirus vector in gene transfer into blood vessel
KR100854917B1 (ko) 2000-03-30 2008-08-27 가부시키가이샤 디나벡크 겐큐쇼 센다이바이러스 벡터를 사용한 ａｉｄｓ 바이러스 백신
CA2413995C (en) * 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
US20030170897A1 (en) * 2000-06-27 2003-09-11 Enyu Imai Virus vector for transferring gene into renal cells
AU2001290273A1 (en) * 2000-10-06 2002-04-22 Dnavec Research Inc. Paramyxovirus vector for transferring foreign gene into skeletal muscle
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
EP1447451A4 (de) * 2001-09-28 2006-06-07 Dnavec Research Inc SÄUGERZELLEN INFIZIERENDER, EPITOPGEBUNDENES BETA2m CODIERENDER VIRUSVEKTOR UND DESSEN VERWENDUNG
EP1504766A4 (de) * 2002-04-30 2006-11-02 Dnavec Research Inc Arzneimittel- oder genträgerzusammensetzung mit verringerter hämagglutinin-aktivität
JPWO2004022731A1 (ja) * 2002-09-04 2005-12-22 株式会社ディナベック研究所 シアル酸結合活性を有する膜蛋白質をエンベロープに含むウイルスベクターをグラム陽性菌由来ノイラミニダーゼを用いて製造する方法
JPWO2004031380A1 (ja) * 2002-10-01 2006-02-02 株式会社ディナベック研究所 ＴＡＰ活性の阻害によりＭＨＣｃｌａｓｓＩによる外来エピトープの提示を増強する方法
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
KR20050100379A (ko) * 2003-01-31 2005-10-18 가부시키가이샤 디나벡크 겐큐쇼 리보자임을 코드하는 파라믹소바이러스 벡터 및 그의 이용
ATE459707T1 (de) * 2003-06-30 2010-03-15 Dnavec Research Inc Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
CA2554198A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Process for producing virus vector
EP2434020B1 (de) 2004-01-22 2014-11-05 Dnavec Research Inc. Verfahren zur Herstellung eines Paramyxoviridae Virusvektors unter Verwendung eines Hybridpromotors, welcher einen Cytomegalovirus Enhancer und einen Hühner-Beta-Actin-Promotor beinhaltet
JP4969444B2 (ja) 2005-06-14 2012-07-04 ディナベック株式会社 抗体の作製方法
EP1950307B8 (de) 2005-10-28 2016-02-24 IP Pharma Co., Ltd. Gentransfer in luftwegepithelstammzelle unter verwendung eines mit rna-virus-spike-protein pseudotypisierten lentivirusvektors
US20100167341A1 (en) 2006-01-17 2010-07-01 Dnavec Corporation Novel protein expression system
WO2007139178A1 (ja) 2006-05-31 2007-12-06 Dnavec Corporation アルツハイマー病治療薬
KR20090114431A (ko) 2007-02-07 2009-11-03 디나벡크 가부시키가이샤 약독화 마이너스 가닥 ｒｎａ 바이러스
JP4936482B2 (ja) * 2007-04-13 2012-05-23 独立行政法人産業技術総合研究所 改良された持続感染型センダイウイルスベクター
EP2143794A1 (de) 2007-04-27 2010-01-13 Kyushu University, National University Corporation Viraler vektor für gentherapie
WO2010008054A1 (ja) 2008-07-16 2010-01-21 ディナベック株式会社 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
US20120088819A1 (en) 2008-10-31 2012-04-12 Makoto Inoue Method for enhancing expression of recombinant protein
CN102711812B (zh) 2010-01-08 2014-07-16 国立大学法人京都大学 Tau蛋白病治疗用疫苗
US9090909B2 (en) 2010-08-30 2015-07-28 Dnavec Corporation Composition for inducing pluripotent stem cell, and use thereof
WO2015046229A1 (ja) 2013-09-24 2015-04-02 ディナベック株式会社 多能性幹細胞の誘導効率を改善する方法
WO2018092887A1 (ja) 2016-11-17 2018-05-24 国立感染症研究所長が代表する日本国 非感染性パラミクソウイルス粒子を用いた感染症ワクチン
CN111479920B (zh) 2017-07-21 2025-08-01 株式会社爱医隆集团 用于修饰靶序列的多核苷酸及其用途
EP3744847A4 (de) 2018-01-22 2021-12-08 Japan as Represented by The Director-General of National Institute of Infectious Diseases Selektives cd8-positives t-zellinduzierendes impfstoffantigen
CN111733170A (zh) * 2020-07-01 2020-10-02 青岛农业大学 一种表达荧光素酶的重组犬麻疹病毒
US20230220025A1 (en) 2020-09-04 2023-07-13 Heartseed Inc. Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells
US20240060051A1 (en) 2020-12-25 2024-02-22 Kyoto University Method for Producing Naive Human IPS Cells From Somatic Cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016538A1 (en) * 1995-10-31 1997-05-09 Dnavec Research Inc. (-)-strand rna virus vector having autonomously replicating activity
CA2236378C (en) 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
EP0912724B1 (de) * 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US6828138B1 (en) 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
US20030166252A1 (en) 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
HK1047959A1 (en) 2000-01-19 2003-03-14 Dnavec Research Inc. Use of paramyxovirus vector in gene transfer into blood vessel
KR100854917B1 (ko) 2000-03-30 2008-08-27 가부시키가이샤 디나벡크 겐큐쇼 센다이바이러스 벡터를 사용한 ａｉｄｓ 바이러스 백신
CA2322057A1 (en) 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CA2413995C (en) 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
US20030170897A1 (en) 2000-06-27 2003-09-11 Enyu Imai Virus vector for transferring gene into renal cells
AU2001290273A1 (en) 2000-10-06 2002-04-22 Dnavec Research Inc. Paramyxovirus vector for transferring foreign gene into skeletal muscle
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
CN100357443C (zh) 2000-11-27 2007-12-26 株式会社载体研究所 编码血管生成基因的副粘病毒载体及其应用

Also Published As

Publication number Publication date
ES2288866T3 (es) 2008-02-01
US20040121308A1 (en) 2004-06-24
DE60035885T2 (de) 2008-05-08
WO2001018223A1 (en) 2001-03-15
AU6872000A (en) 2001-04-10
KR20020013565A (ko) 2002-02-20
JP3748535B2 (ja) 2006-02-22
US7144579B2 (en) 2006-12-05
HK1047450A1 (zh) 2003-02-21
EP1211318B1 (de) 2007-08-08
KR100776086B1 (ko) 2007-11-15
DE60035885D1 (de) 2007-09-20
EP1211318A4 (de) 2003-08-13
EP1211318A1 (de) 2002-06-05
DK1211318T3 (da) 2007-11-12
CN1367839A (zh) 2002-09-04
CA2376106A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
DK1211318T3 (da) Paramyxovira omfattende en modificeret transkriptionsstartsekvens
UA92132C2 (ru) Высокоактивные рекомбинантные вирусы гриппа для вакцин и генотерапии
TW200636070A (en) Rescue of influenza virus
ATE172642T1 (de) Impfstoffe und verfahren zu ihrer herstellung
WO2016097065A1 (en) Ebolavirus and marburgvirus vaccines
IL199126A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters.
ATE437175T1 (de) Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen
IL188362A0 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
IL182512A0 (en) Method for producing recombinant viruses of the mononegavirales order
WO2006136448A3 (en) Attenuated sars and use as a vaccine
EP1989316A4 (de) Verfahren zur herstellung von rekombinantem virus, dna-konstrukte, rekombinantes virus und impfstoffzusammensetzungen
DE60302848D1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
WO2003072771A3 (en) Method of preparing a treatment product using a togaviridae expression construct
DE69939938D1 (de) Nukleinsäuresequenzen zur potenzierung der expression eines nützlichen gens und dessen verfahren
WO2024238641A3 (en) Methods for identification and selection of self-replicating rna molecules for biomedical applications
MX2019014819A (es) Plásmido para inserción simplificada de secuencias cortas de adn en un cistrón que codifica para una proteína de cápside potyviral y método de aplicación.
Leitner Immune-Activating Mechanisms of Replicase-Based DNA and RNA Vaccines and Their Role in Immune-Apoptosis
WO2007050102A3 (en) Dendritic cell based vaccines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1211318

Country of ref document: EP

REN Ceased due to non-payment of the annual fee